Pavir Tablets 250 mg (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer this drug 250 mg orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer this drug 125 mg orally 2 times daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer this drug 250 mg orally 2 times daily. Discontinue treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment Because creatinine clearance of this drug is reduced in patients with renal impairment, dose adjustment should be made with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose, 2 times daily 10～29 250 mg per dose, 1 time daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 125 mg per dose, 2 times daily 10～29 125 mg per dose, 1 time daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose, 2 times daily 10～29 125 mg per dose, 2 times daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours is preferable, taking the interval between dialysis sessions into account. A 4-hour hemodialysis session reduces the plasma concentration of this drug by approximately 75%; therefore, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment No dose adjustment is required in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This drug should not be administered to certain patients. Patients who have had an allergic reaction to this medication or its components should not use it. This medication contains lactose, so patients with lactose intolerance or certain genetic metabolic disorders should also avoid it. Patients with impaired renal function should use this drug with caution, and dosage adjustments may be necessary. While taking this medication, symptoms such as headache, nausea, dizziness, and drowsiness may occur, and especially in the elderly, drowsiness and confusion may occur more frequently. Rarely, blood-related abnormalities such as thrombocytopenia or leukopenia may occur. Gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea are commonly reported, and liver function abnormalities or jaundice may occur rarely. Skin rashes or itching are common, and severe skin reactions may occur rarely. Acute renal failure has been reported rarely in patients with poor renal function. This drug does not cure genital herpes, so it is important to avoid sexual contact and maintain safe sexual relations when symptoms are present. If dizziness or drowsiness is experienced while taking this medication, driving or operating machinery should be avoided. Patients with mild to moderate liver dysfunction do not require special dosage adjustments, but those with severe liver impairment should be cautious as the drug’s efficacy may be reduced. This drug has little interaction with other medications; however, care should be taken when taken with certain medications, such as probenecid, as this may raise blood levels and increase toxicity risk. Women who are pregnant or breastfeeding should carefully consider the benefits and risks of taking this medication. Safety and efficacy in children under 18 years have not been confirmed, so it is advisable not to use it. Generally, elderly patients do not need dosage adjustments, but adjustments may be necessary if renal function is reduced. In case of overdose, appropriate treatment should be taken and blood dialysis may be helpful. This drug should be stored in a dry place at temperatures below 30 degrees Celsius, out of reach of children. Special care should be taken not to transfer to another container, as this may affect the quality.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. Additionally, it is important to store it in a cool, dry place below 25 degrees Celsius.

Appearance

Round film-coated tablets, white or pale yellow

Package unit

21 tablets (7 tablets/PTP x 3)